| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 54 | 2024 | 3455 | 5.000 |
Why?
|
| Neuroblastoma | 31 | 2024 | 1250 | 4.520 |
Why?
|
| Brain Neoplasms | 82 | 2024 | 9031 | 3.920 |
Why?
|
| Radiation-Sensitizing Agents | 12 | 2022 | 350 | 2.480 |
Why?
|
| Central Nervous System Neoplasms | 11 | 2023 | 916 | 1.940 |
Why?
|
| Glioblastoma | 33 | 2023 | 3482 | 1.710 |
Why?
|
| Ependymoma | 6 | 2023 | 320 | 1.470 |
Why?
|
| Medulloblastoma | 5 | 2023 | 678 | 1.360 |
Why?
|
| Histone Deacetylase Inhibitors | 7 | 2018 | 774 | 1.320 |
Why?
|
| 3-Iodobenzylguanidine | 12 | 2022 | 114 | 1.220 |
Why?
|
| Infratentorial Neoplasms | 2 | 2019 | 98 | 1.200 |
Why?
|
| TOR Serine-Threonine Kinases | 13 | 2023 | 2057 | 1.180 |
Why?
|
| Pineal Gland | 3 | 2019 | 158 | 1.180 |
Why?
|
| Brain Stem Neoplasms | 8 | 2018 | 190 | 1.090 |
Why?
|
| Radiation Injuries | 7 | 2020 | 1189 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2024 | 9281 | 1.060 |
Why?
|
| PTEN Phosphohydrolase | 15 | 2012 | 1115 | 1.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 7 | 2005 | 412 | 0.980 |
Why?
|
| Brain Stem | 3 | 2019 | 858 | 0.940 |
Why?
|
| Cerebellar Neoplasms | 4 | 2023 | 586 | 0.920 |
Why?
|
| Craniopharyngioma | 2 | 2020 | 277 | 0.910 |
Why?
|
| Pyrimidines | 7 | 2022 | 3028 | 0.900 |
Why?
|
| Radiation Oncology | 8 | 2023 | 563 | 0.890 |
Why?
|
| Radiotherapy Dosage | 13 | 2024 | 2898 | 0.880 |
Why?
|
| Combined Modality Therapy | 31 | 2022 | 8528 | 0.870 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2017 | 549 | 0.840 |
Why?
|
| Antineoplastic Agents | 23 | 2018 | 13642 | 0.820 |
Why?
|
| Cranial Irradiation | 8 | 2021 | 390 | 0.820 |
Why?
|
| Phosphatidylinositol 3-Kinases | 13 | 2023 | 2865 | 0.810 |
Why?
|
| Growth | 2 | 2014 | 365 | 0.790 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2024 | 2057 | 0.790 |
Why?
|
| Germinoma | 3 | 2019 | 132 | 0.790 |
Why?
|
| Enzyme Inhibitors | 13 | 2013 | 3713 | 0.790 |
Why?
|
| Dacarbazine | 6 | 2017 | 559 | 0.780 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2022 | 491 | 0.780 |
Why?
|
| Radiosurgery | 9 | 2023 | 1342 | 0.770 |
Why?
|
| Child | 84 | 2024 | 80157 | 0.760 |
Why?
|
| Neoplasms, Second Primary | 5 | 2021 | 1052 | 0.760 |
Why?
|
| Photons | 3 | 2020 | 589 | 0.760 |
Why?
|
| Neoplasms | 23 | 2023 | 22172 | 0.750 |
Why?
|
| Radiation Tolerance | 10 | 2013 | 479 | 0.740 |
Why?
|
| Child, Preschool | 56 | 2024 | 42231 | 0.700 |
Why?
|
| Chromones | 7 | 2011 | 148 | 0.680 |
Why?
|
| Cell Cycle Proteins | 8 | 2023 | 3449 | 0.650 |
Why?
|
| DNA Damage | 5 | 2024 | 2449 | 0.650 |
Why?
|
| Morpholines | 8 | 2019 | 581 | 0.640 |
Why?
|
| Bone Neoplasms | 6 | 2020 | 2529 | 0.630 |
Why?
|
| Pituitary Neoplasms | 2 | 2020 | 1324 | 0.600 |
Why?
|
| Apoptosis | 18 | 2019 | 9491 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2019 | 2918 | 0.590 |
Why?
|
| Gamma Rays | 3 | 2019 | 318 | 0.580 |
Why?
|
| Prognosis | 28 | 2023 | 29629 | 0.580 |
Why?
|
| Humans | 208 | 2024 | 761578 | 0.580 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2011 | 2805 | 0.570 |
Why?
|
| Executive Function | 3 | 2016 | 1392 | 0.570 |
Why?
|
| Quinolones | 4 | 2011 | 378 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-akt | 10 | 2023 | 2457 | 0.550 |
Why?
|
| Histone Deacetylases | 3 | 2018 | 720 | 0.550 |
Why?
|
| Radiotherapy | 12 | 2023 | 1499 | 0.550 |
Why?
|
| Sarcoma | 4 | 2022 | 1801 | 0.550 |
Why?
|
| Pinealoma | 1 | 2016 | 52 | 0.530 |
Why?
|
| Prodrugs | 3 | 2007 | 261 | 0.520 |
Why?
|
| Neurocytoma | 1 | 2016 | 29 | 0.520 |
Why?
|
| Neoplasm, Residual | 2 | 2020 | 1008 | 0.510 |
Why?
|
| Pyrazoles | 4 | 2019 | 2009 | 0.490 |
Why?
|
| Adolescent | 56 | 2024 | 88323 | 0.490 |
Why?
|
| Mutation | 20 | 2024 | 30054 | 0.490 |
Why?
|
| Hydroxamic Acids | 3 | 2015 | 481 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2019 | 2425 | 0.470 |
Why?
|
| Cell Line, Tumor | 28 | 2019 | 16990 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2022 | 11742 | 0.460 |
Why?
|
| Infant | 33 | 2024 | 36193 | 0.450 |
Why?
|
| Mice, Nude | 11 | 2019 | 3614 | 0.440 |
Why?
|
| Indoles | 4 | 2019 | 1833 | 0.440 |
Why?
|
| Survival Rate | 17 | 2021 | 12725 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2019 | 5672 | 0.420 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2017 | 1784 | 0.420 |
Why?
|
| Male | 86 | 2024 | 360841 | 0.410 |
Why?
|
| Disease-Free Survival | 10 | 2019 | 6815 | 0.410 |
Why?
|
| Female | 95 | 2024 | 392688 | 0.400 |
Why?
|
| Whole-Body Irradiation | 4 | 2023 | 433 | 0.400 |
Why?
|
| Pons | 2 | 2011 | 240 | 0.400 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2023 | 263 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2022 | 8553 | 0.390 |
Why?
|
| Iodine Radioisotopes | 5 | 2022 | 1031 | 0.390 |
Why?
|
| Dose-Response Relationship, Radiation | 7 | 2023 | 882 | 0.380 |
Why?
|
| Survival Analysis | 19 | 2020 | 10090 | 0.380 |
Why?
|
| Sulfonamides | 3 | 2016 | 1978 | 0.370 |
Why?
|
| Indazoles | 1 | 2013 | 304 | 0.370 |
Why?
|
| Health Status | 2 | 2014 | 4077 | 0.360 |
Why?
|
| Cell Cycle | 8 | 2015 | 2932 | 0.360 |
Why?
|
| NF-kappa B | 2 | 2018 | 2490 | 0.360 |
Why?
|
| Tumor Cells, Cultured | 17 | 2019 | 6132 | 0.360 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2010 | 21 | 0.350 |
Why?
|
| Radiation | 1 | 2009 | 49 | 0.340 |
Why?
|
| Salvage Therapy | 5 | 2021 | 1264 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2023 | 4514 | 0.340 |
Why?
|
| Signal Transduction | 13 | 2019 | 23447 | 0.330 |
Why?
|
| Butyrates | 2 | 2007 | 169 | 0.330 |
Why?
|
| Young Adult | 31 | 2024 | 59254 | 0.330 |
Why?
|
| Retrospective Studies | 36 | 2024 | 80646 | 0.330 |
Why?
|
| Medical Oncology | 3 | 2023 | 2321 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2020 | 3605 | 0.320 |
Why?
|
| Meningeal Neoplasms | 3 | 2023 | 1248 | 0.310 |
Why?
|
| Gliosarcoma | 1 | 2008 | 114 | 0.310 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2020 | 617 | 0.310 |
Why?
|
| Astrocytes | 6 | 2008 | 1346 | 0.300 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2009 | 126 | 0.300 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3466 | 0.290 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 328 | 0.290 |
Why?
|
| Treatment Outcome | 25 | 2023 | 64684 | 0.280 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2008 | 136 | 0.280 |
Why?
|
| Phenylbutyrates | 1 | 2007 | 72 | 0.270 |
Why?
|
| Protein Kinases | 3 | 2009 | 1608 | 0.270 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 1661 | 0.270 |
Why?
|
| Caspases | 3 | 2006 | 879 | 0.270 |
Why?
|
| Astrocytoma | 3 | 2019 | 775 | 0.270 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 39107 | 0.270 |
Why?
|
| Pandemics | 3 | 2021 | 8656 | 0.270 |
Why?
|
| Quality of Life | 5 | 2023 | 13367 | 0.260 |
Why?
|
| Butyric Acid | 1 | 2005 | 51 | 0.260 |
Why?
|
| Necrosis | 3 | 2019 | 1611 | 0.260 |
Why?
|
| Mice | 27 | 2023 | 81539 | 0.260 |
Why?
|
| G1 Phase | 6 | 2005 | 403 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1705 | 0.260 |
Why?
|
| Radiopharmaceuticals | 6 | 2017 | 2651 | 0.250 |
Why?
|
| Quinazolines | 5 | 2011 | 1371 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 4 | 2012 | 5790 | 0.240 |
Why?
|
| Cholangiocarcinoma | 1 | 2010 | 552 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6484 | 0.240 |
Why?
|
| Radiotherapy, Conformal | 2 | 2023 | 548 | 0.240 |
Why?
|
| Adult | 44 | 2023 | 221200 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2023 | 801 | 0.240 |
Why?
|
| Berberine | 1 | 2004 | 26 | 0.230 |
Why?
|
| Piperidines | 1 | 2013 | 1656 | 0.230 |
Why?
|
| Radiation Dosage | 4 | 2022 | 1958 | 0.230 |
Why?
|
| Drug Delivery Systems | 3 | 2021 | 2226 | 0.230 |
Why?
|
| Supratentorial Neoplasms | 1 | 2005 | 159 | 0.230 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 3617 | 0.230 |
Why?
|
| Stem Cell Transplantation | 4 | 2019 | 1600 | 0.230 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 422 | 0.230 |
Why?
|
| Isotretinoin | 4 | 2018 | 134 | 0.230 |
Why?
|
| Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
| Growth Charts | 1 | 2023 | 60 | 0.220 |
Why?
|
| Cell Hypoxia | 2 | 2005 | 657 | 0.220 |
Why?
|
| Animals | 32 | 2024 | 168475 | 0.220 |
Why?
|
| DNA Methylation | 4 | 2012 | 4399 | 0.210 |
Why?
|
| Disease Progression | 11 | 2021 | 13510 | 0.210 |
Why?
|
| Blotting, Western | 8 | 2011 | 5036 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 4 | 2019 | 883 | 0.210 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 5799 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2021 | 5305 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 2872 | 0.200 |
Why?
|
| Uridine | 1 | 2022 | 141 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2017 | 858 | 0.190 |
Why?
|
| Fund Raising | 1 | 2021 | 49 | 0.190 |
Why?
|
| Genes, p53 | 4 | 2012 | 712 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 2811 | 0.190 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2001 | 110 | 0.180 |
Why?
|
| Statistics, Nonparametric | 5 | 2020 | 2850 | 0.180 |
Why?
|
| Cell Proliferation | 10 | 2019 | 10451 | 0.180 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 496 | 0.180 |
Why?
|
| Relative Biological Effectiveness | 2 | 2020 | 312 | 0.180 |
Why?
|
| Neurosurgical Procedures | 4 | 2018 | 2072 | 0.170 |
Why?
|
| Ribonuclease III | 1 | 2022 | 279 | 0.170 |
Why?
|
| Patient Isolation | 1 | 2020 | 100 | 0.170 |
Why?
|
| Models, Neurological | 1 | 2008 | 1769 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2017 | 92 | 0.170 |
Why?
|
| DNA Glycosylases | 1 | 2020 | 125 | 0.170 |
Why?
|
| Memantine | 1 | 2020 | 108 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 384 | 0.160 |
Why?
|
| Prospective Studies | 13 | 2023 | 54423 | 0.160 |
Why?
|
| Standard of Care | 2 | 2021 | 551 | 0.160 |
Why?
|
| Tumor Burden | 3 | 2019 | 1893 | 0.160 |
Why?
|
| Radiation, Ionizing | 3 | 2013 | 251 | 0.160 |
Why?
|
| DNA Repair | 4 | 2024 | 2046 | 0.160 |
Why?
|
| Incidence | 10 | 2023 | 21355 | 0.160 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 11120 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2024 | 36426 | 0.150 |
Why?
|
| Furans | 2 | 2010 | 202 | 0.150 |
Why?
|
| Teratoma | 2 | 2016 | 404 | 0.150 |
Why?
|
| Loneliness | 1 | 2020 | 203 | 0.150 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2017 | 332 | 0.150 |
Why?
|
| Vincristine | 3 | 2021 | 1036 | 0.150 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 3 | 2015 | 66 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 2297 | 0.150 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2018 | 82 | 0.150 |
Why?
|
| SEER Program | 5 | 2022 | 1450 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 448 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
| Prescriptions | 1 | 2020 | 386 | 0.150 |
Why?
|
| Hospices | 1 | 2020 | 245 | 0.150 |
Why?
|
| Radiobiology | 1 | 2018 | 90 | 0.150 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 12463 | 0.140 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 152 | 0.140 |
Why?
|
| Texas | 1 | 2018 | 404 | 0.140 |
Why?
|
| Florida | 1 | 2018 | 431 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 297 | 0.140 |
Why?
|
| Pyridines | 4 | 2016 | 2875 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 871 | 0.140 |
Why?
|
| Radiation Monitoring | 1 | 2017 | 103 | 0.140 |
Why?
|
| Blood-Brain Barrier | 2 | 2017 | 1027 | 0.130 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 21019 | 0.130 |
Why?
|
| Age of Onset | 2 | 2017 | 3306 | 0.130 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2016 | 25 | 0.130 |
Why?
|
| Pyrimidinones | 2 | 2019 | 385 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2001 | 1076 | 0.130 |
Why?
|
| Prostatic Neoplasms | 3 | 2021 | 11122 | 0.130 |
Why?
|
| Extremities | 1 | 2001 | 867 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 13382 | 0.120 |
Why?
|
| Patient Care | 1 | 2021 | 622 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2003 | 1062 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2021 | 1176 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 3 | 2009 | 2693 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2023 | 3816 | 0.120 |
Why?
|
| Transcription Factors | 5 | 2011 | 12130 | 0.120 |
Why?
|
| Middle Aged | 24 | 2020 | 220917 | 0.120 |
Why?
|
| S Phase | 1 | 2016 | 421 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2006 | 360 | 0.120 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 125 | 0.120 |
Why?
|
| Retinoblastoma Protein | 2 | 2016 | 672 | 0.120 |
Why?
|
| Histones | 4 | 2015 | 2580 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 4317 | 0.120 |
Why?
|
| Tissue Distribution | 3 | 2019 | 2264 | 0.120 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 670 | 0.120 |
Why?
|
| Health Resources | 1 | 2020 | 935 | 0.120 |
Why?
|
| Acetylation | 3 | 2015 | 1055 | 0.110 |
Why?
|
| Glucose | 1 | 2006 | 4347 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 210 | 0.110 |
Why?
|
| Cell Survival | 5 | 2016 | 5791 | 0.110 |
Why?
|
| HIV Infections | 1 | 2020 | 17352 | 0.110 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 56 | 0.110 |
Why?
|
| Phosphorylation | 5 | 2009 | 8321 | 0.110 |
Why?
|
| Aged | 19 | 2021 | 169308 | 0.110 |
Why?
|
| Cysts | 1 | 2019 | 681 | 0.110 |
Why?
|
| Immunomagnetic Separation | 1 | 2013 | 79 | 0.110 |
Why?
|
| Intraoperative Period | 2 | 2007 | 510 | 0.110 |
Why?
|
| Risk | 7 | 2021 | 9610 | 0.110 |
Why?
|
| Uncertainty | 1 | 2018 | 754 | 0.110 |
Why?
|
| DNA, Neoplasm | 4 | 2012 | 1745 | 0.110 |
Why?
|
| Transplantation, Autologous | 4 | 2019 | 2115 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2005 | 319 | 0.100 |
Why?
|
| Meningioma | 1 | 2021 | 1218 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2014 | 181 | 0.100 |
Why?
|
| Survivors | 3 | 2016 | 2371 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2022 | 1406 | 0.100 |
Why?
|
| Drug Synergism | 3 | 2011 | 1757 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1858 | 0.100 |
Why?
|
| Flow Cytometry | 6 | 2011 | 5870 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5315 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 1157 | 0.100 |
Why?
|
| Sirolimus | 5 | 2017 | 1533 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 888 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7391 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 263 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 2199 | 0.100 |
Why?
|
| Anesthesia | 1 | 2023 | 1595 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2019 | 1609 | 0.100 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 7593 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 115 | 0.090 |
Why?
|
| Phosphorylcholine | 1 | 2011 | 153 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2011 | 68 | 0.090 |
Why?
|
| Lactic Acid | 3 | 2011 | 1139 | 0.090 |
Why?
|
| Leadership | 1 | 2020 | 1385 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 368 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2001 | 4937 | 0.090 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2017 | 938 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 129 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2013 | 731 | 0.090 |
Why?
|
| Mitolactol | 1 | 2010 | 13 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2001 | 2898 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1120 | 0.090 |
Why?
|
| Thioguanine | 1 | 2010 | 45 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 15266 | 0.090 |
Why?
|
| Procarbazine | 1 | 2010 | 172 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2012 | 456 | 0.090 |
Why?
|
| Lomustine | 1 | 2010 | 60 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1972 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1813 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 4915 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2011 | 3769 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 2020 | 0.080 |
Why?
|
| Time Factors | 7 | 2022 | 39970 | 0.080 |
Why?
|
| Sulfites | 1 | 2009 | 83 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 326 | 0.080 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 346 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2021 | 1958 | 0.080 |
Why?
|
| Carbon Isotopes | 1 | 2010 | 458 | 0.080 |
Why?
|
| Infant, Newborn | 4 | 2021 | 26198 | 0.080 |
Why?
|
| Aniline Compounds | 2 | 2019 | 1069 | 0.080 |
Why?
|
| Clinical Clerkship | 1 | 2015 | 564 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 8002 | 0.080 |
Why?
|
| Massachusetts | 2 | 2021 | 8830 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2021 | 23996 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 909 | 0.080 |
Why?
|
| Patient Selection | 2 | 2017 | 4244 | 0.080 |
Why?
|
| Luminescent Proteins | 1 | 2011 | 837 | 0.080 |
Why?
|
| Recurrence | 5 | 2023 | 8466 | 0.080 |
Why?
|
| Cell Death | 1 | 2013 | 1679 | 0.080 |
Why?
|
| Autophagy | 2 | 2019 | 1327 | 0.080 |
Why?
|
| E2F1 Transcription Factor | 2 | 2006 | 178 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2024 | 3359 | 0.070 |
Why?
|
| Bone Marrow Purging | 2 | 2009 | 108 | 0.070 |
Why?
|
| United States | 9 | 2022 | 72335 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 9420 | 0.070 |
Why?
|
| Cell Line, Transformed | 2 | 2007 | 866 | 0.070 |
Why?
|
| Cohort Studies | 8 | 2016 | 41493 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2011 | 9610 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2827 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2005 | 2644 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 1898 | 0.070 |
Why?
|
| Positron-Emission Tomography | 3 | 2012 | 6485 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 3639 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 1246 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3205 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2015 | 2495 | 0.070 |
Why?
|
| Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2005 | 619 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2005 | 2919 | 0.070 |
Why?
|
| Communication | 1 | 2020 | 3873 | 0.070 |
Why?
|
| Proteins | 1 | 2001 | 6032 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2020 | 3980 | 0.070 |
Why?
|
| Neuroglia | 2 | 2019 | 956 | 0.060 |
Why?
|
| Remission Induction | 2 | 2003 | 2397 | 0.060 |
Why?
|
| Transplantation, Heterologous | 3 | 2011 | 2386 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 2578 | 0.060 |
Why?
|
| Risk Factors | 4 | 2019 | 74212 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2006 | 190 | 0.060 |
Why?
|
| Cell Line | 4 | 2016 | 15601 | 0.060 |
Why?
|
| Piperazines | 1 | 2016 | 2523 | 0.060 |
Why?
|
| Enzyme Induction | 1 | 2006 | 452 | 0.060 |
Why?
|
| Serine | 1 | 2009 | 831 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2006 | 333 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6228 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1351 | 0.060 |
Why?
|
| Transfection | 5 | 2004 | 5774 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4330 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3889 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2656 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 14607 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 4 | 2017 | 6214 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2022 | 1336 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2010 | 1646 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 2169 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 2020 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2009 | 1202 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 140 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 1616 | 0.060 |
Why?
|
| Physicians | 1 | 2021 | 4591 | 0.050 |
Why?
|
| Aortic Diseases | 1 | 2009 | 735 | 0.050 |
Why?
|
| G2 Phase | 1 | 2003 | 136 | 0.050 |
Why?
|
| Cisplatin | 3 | 2009 | 1652 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2007 | 329 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2016 | 732 | 0.050 |
Why?
|
| Life Tables | 1 | 2003 | 364 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 673 | 0.050 |
Why?
|
| Biopsy | 3 | 2019 | 6766 | 0.050 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5247 | 0.050 |
Why?
|
| Choriocarcinoma | 1 | 2003 | 121 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2005 | 576 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2005 | 3597 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 3597 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Lymphokines | 2 | 2003 | 927 | 0.050 |
Why?
|
| Brain | 5 | 2022 | 27121 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3429 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2011 | 12794 | 0.050 |
Why?
|
| Gene Amplification | 3 | 2015 | 1089 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5336 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 1779 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 2010 | 0.050 |
Why?
|
| Students, Medical | 1 | 2015 | 1936 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5709 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2009 | 2220 | 0.050 |
Why?
|
| Aorta | 1 | 2009 | 2041 | 0.050 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2001 | 27 | 0.050 |
Why?
|
| Oncogenes | 1 | 2007 | 1222 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2001 | 48 | 0.050 |
Why?
|
| Carcinoma | 1 | 2013 | 2330 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2005 | 899 | 0.050 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2003 | 220 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9542 | 0.050 |
Why?
|
| Metabolomics | 1 | 2010 | 1659 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2005 | 1638 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 678 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2005 | 2510 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2009 | 2224 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 209 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 6312 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2001 | 184 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 2021 | 111 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6346 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2008 | 1819 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 397 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 1989 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 10766 | 0.040 |
Why?
|
| Protein Kinase C-alpha | 1 | 2019 | 113 | 0.040 |
Why?
|
| Lymphatic Abnormalities | 1 | 2021 | 134 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2007 | 1030 | 0.040 |
Why?
|
| Random Allocation | 1 | 2023 | 2395 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 413 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2004 | 3492 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2006 | 1808 | 0.040 |
Why?
|
| Antioxidants | 1 | 2006 | 1668 | 0.040 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1998 | 201 | 0.040 |
Why?
|
| Acrylamides | 1 | 2019 | 260 | 0.040 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 374 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 784 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 655 | 0.040 |
Why?
|
| X-Rays | 2 | 1996 | 307 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 2000 | 401 | 0.040 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2017 | 40 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4853 | 0.040 |
Why?
|
| Mitochondria | 2 | 2010 | 3624 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1998 | 1085 | 0.030 |
Why?
|
| Age Factors | 2 | 2013 | 18398 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 428 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 4243 | 0.030 |
Why?
|
| Proteomics | 1 | 2010 | 3848 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 3201 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2000 | 333 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 621 | 0.030 |
Why?
|
| COS Cells | 1 | 1998 | 1130 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 560 | 0.030 |
Why?
|
| Purines | 1 | 2019 | 607 | 0.030 |
Why?
|
| Retroviridae | 1 | 1999 | 850 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2019 | 323 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1232 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 11076 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2004 | 4125 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2021 | 709 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1651 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 799 | 0.030 |
Why?
|
| Aphidicolin | 1 | 1995 | 37 | 0.030 |
Why?
|
| Oligodendroglia | 1 | 2019 | 538 | 0.030 |
Why?
|
| Vascular Malformations | 1 | 2021 | 468 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
| Cell Movement | 1 | 2007 | 5205 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2008 | 426 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2927 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3113 | 0.030 |
Why?
|
| Gender Identity | 1 | 2021 | 766 | 0.030 |
Why?
|
| Phospholipids | 1 | 1998 | 786 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2005 | 4142 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 473 | 0.030 |
Why?
|
| Models, Biological | 2 | 2009 | 9469 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3123 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 6075 | 0.030 |
Why?
|
| Sex Factors | 2 | 2021 | 10554 | 0.030 |
Why?
|
| France | 1 | 2015 | 497 | 0.030 |
Why?
|
| Hospice Care | 1 | 2020 | 678 | 0.030 |
Why?
|
| Infection Control | 1 | 2021 | 982 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 4740 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 4465 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2016 | 350 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2022 | 2526 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3606 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 6534 | 0.030 |
Why?
|
| Medicare | 2 | 2021 | 6770 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 622 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 561 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2018 | 1281 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 16592 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 2915 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1486 | 0.030 |
Why?
|
| Transcriptional Activation | 3 | 2004 | 1756 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 1935 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 733 | 0.020 |
Why?
|
| Neutropenia | 1 | 2017 | 885 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2707 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4063 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2004 | 193 | 0.020 |
Why?
|
| International Cooperation | 1 | 2018 | 1422 | 0.020 |
Why?
|
| Imidazoles | 2 | 2010 | 1180 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 1432 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 719 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 2469 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4576 | 0.020 |
Why?
|
| Algorithms | 2 | 2022 | 14032 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1440 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 9758 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 1125 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2007 | 2065 | 0.020 |
Why?
|
| Microglia | 1 | 2019 | 1362 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2001 | 2979 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2010 | 194 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2017 | 815 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1378 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26127 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2012 | 662 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 748 | 0.020 |
Why?
|
| Leukemia | 1 | 2018 | 1522 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7213 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 1768 | 0.020 |
Why?
|
| Chloroquine | 1 | 2010 | 274 | 0.020 |
Why?
|
| Toluene | 1 | 2008 | 32 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1999 | 3396 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2775 | 0.020 |
Why?
|
| Health Facilities | 1 | 2014 | 580 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 897 | 0.020 |
Why?
|
| Diffusion | 1 | 2011 | 814 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 330 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2015 | 962 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2023 | 5079 | 0.020 |
Why?
|
| Plasmids | 2 | 2004 | 2269 | 0.020 |
Why?
|
| Cause of Death | 1 | 2019 | 3683 | 0.020 |
Why?
|
| Neck | 1 | 2013 | 734 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3514 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 629 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 1968 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2008 | 247 | 0.020 |
Why?
|
| Aortography | 1 | 2009 | 421 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2000 | 2223 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 1751 | 0.020 |
Why?
|
| Hippocampus | 1 | 2020 | 3766 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5821 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 11904 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 634 | 0.020 |
Why?
|
| Anisotropy | 1 | 2010 | 1283 | 0.020 |
Why?
|
| Radiology | 1 | 2021 | 2113 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 4425 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2014 | 2696 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2557 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2006 | 108 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 20099 | 0.020 |
Why?
|
| Mitomycin | 1 | 2007 | 263 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 413 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9319 | 0.020 |
Why?
|
| Biological Availability | 1 | 2006 | 390 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 1229 | 0.020 |
Why?
|
| Dipeptides | 1 | 2007 | 391 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 459 | 0.020 |
Why?
|
| Gene Deletion | 2 | 2005 | 2665 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3801 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2005 | 162 | 0.020 |
Why?
|
| Quinolines | 1 | 2010 | 765 | 0.020 |
Why?
|
| Plicamycin | 1 | 2004 | 12 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9646 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 162 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3358 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 952 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1971 | 0.010 |
Why?
|
| Densitometry | 1 | 2004 | 151 | 0.010 |
Why?
|
| Research | 1 | 2012 | 1982 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2017 | 7859 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2005 | 279 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 754 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 10212 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 58983 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 92 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2017 | 8633 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2007 | 1341 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 7054 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2008 | 1699 | 0.010 |
Why?
|
| Choline | 1 | 2005 | 515 | 0.010 |
Why?
|
| Syndrome | 1 | 2009 | 3267 | 0.010 |
Why?
|
| Creatine | 1 | 2005 | 427 | 0.010 |
Why?
|
| Laminin | 1 | 2004 | 408 | 0.010 |
Why?
|
| Base Sequence | 2 | 2004 | 12441 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 1545 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 2016 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14665 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2007 | 1642 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3743 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4281 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 864 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 803 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 4251 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2007 | 2601 | 0.010 |
Why?
|
| Phosphates | 1 | 2004 | 770 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10721 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 687 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1529 | 0.010 |
Why?
|
| Phosphofructokinase-1 | 1 | 2000 | 51 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 1085 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 2000 | 138 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 148 | 0.010 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2010 | 2400 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2000 | 97 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1844 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 2000 | 269 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2000 | 555 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 318 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2014 | 3801 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 282 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2003 | 1494 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 4021 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 2048 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 12990 | 0.010 |
Why?
|
| Ceramides | 1 | 1999 | 201 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2000 | 435 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4811 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2005 | 1902 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 2638 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 2832 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 6056 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1996 | 198 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 3430 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2000 | 1687 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 6180 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2645 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 9001 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 18255 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 7581 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 18966 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 9353 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 17635 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3733 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 2418 | 0.010 |
Why?
|
| Mitosis | 1 | 1996 | 1188 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 1393 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 6374 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 22173 | 0.000 |
Why?
|
| Lung | 1 | 2006 | 10002 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20569 | 0.000 |
Why?
|